Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 22;13(8):2438.
doi: 10.3390/jcm13082438.

Vein of Marshall Ethanol Infusion for AF Ablation; A Review

Louisa O'Neill  1   2   3 , Benjamin De Becker  1 , Maarten De Smet  1 , Clara Francois  1 , Rene Tavernier  1 , Mattias Duytschaever  1 , Jean-Benoit Le Polain De Waroux  1 , Sebastien Knecht  1
Affiliations
Review

Vein of Marshall Ethanol Infusion for AF Ablation; A Review

Louisa O'Neill et al. J Clin Med. .

Abstract

The outcomes of persistent atrial fibrillation (AF) ablation are modest with various adjunctive strategies beyond pulmonary vein isolation (PVI) yielding largely disappointing results in randomised controlled trials. Linear ablation is a commonly employed adjunct strategy but is limited by difficulty in achieving durable bidirectional block, particularly at the mitral isthmus. Epicardial connections play a role in AF initiation and perpetuation. The ligament of Marshall has been implicated as a source of AF triggers and is known to harbour sympathetic and parasympathetic nerve fibres that contribute to AF perpetuation. Ethanol infusion into the Vein of Marshall, a remnant of the superior vena cava and key component of the ligament of Marshall, may eliminate these AF triggers and can facilitate the ease of obtaining durable mitral isthmus block. While early trials have demonstrated the potential of Vein of Marshall 'ethanolisation' to reduce arrhythmia recurrence after persistent AF ablation, further randomised trials are needed to fully determine the potential long-term outcome benefits afforded by this technique.

Keywords: Vein of Marshall; atrial fibrillation; ethanol infusion; mitral isthmus ablation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Contrast injection of Vein of Marshall (VoM) (red arrow) through the internal mammary artery (IMA) catheter in the right anterior oblique (RAO) view. Pentaray catheter is visualised in left atrium. Decapolar catheter in coronary sinus. IMA = internal mammary artery, RAO = right anterior oblique.
Figure 2
Figure 2
(Top panel): voltage map before VoM ethanolisation. (Bottom panel): voltage map demonstrating VoM ‘effect’ with new area of confluent scar inferior and anterior to left pulmonary veins. Ablation tags at mitral isthmus indicate the site of endocardial ablation performed to achieve mitral isthmus block post VoM ethanolisation.
Figure 3
Figure 3
Effects of VoM ethanol infusion on posterior wall, with extensive low voltage seen both panels (right sided veins already isolated in right panel).
See this image and copyright information in PMC

References

    1. Krijthe B.P., Kunst A., Benjamin E.J., Lip G.Y.H., Franco O.H., Hofman A., Witteman J.C.M., Stricker B.H., Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 2013;34:2746–2751. doi: 10.1093/eurheartj/eht280. - DOI - PMC - PubMed
    1. Duytschaever M., De Pooter J., Demolder A., El Haddad M., Phlips T., Strisciuglio T., Debonnaire P., Wolf M., Vandekerckhove Y., Knecht S., et al. Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: The CLOSE to CURE study. Heart Rhythm. 2020;17:535–543. doi: 10.1016/j.hrthm.2019.11.004. - DOI - PubMed
    1. O’Neill L., Almorad A., El Haddad M., Wielandts J.-Y., Gillis K., Hilfiker G., de Becker B., Lycke M., Tavernier R., le Polain de Waroux J.-B., et al. Impact of Catheter Ablation on Arrhythmia Burden in Patients With Shock-Resistant Persistent Atrial Fibrillation. JACC Clin. Electrophysiol. 2023;9:2071–2081. doi: 10.1016/j.jacep.2023.06.004. - DOI - PubMed
    1. Chew D.S., Li Z., Steinberg B.A., O’Brien E.C., Pritchard J., Bunch T.J., Mark D.B., Patel M.R., Nabutovsky Y., Greiner M.A., et al. Arrhythmic Burden and the Risk of Cardiovascular Outcomes in Patients With Paroxysmal Atrial Fibrillation and Cardiac Implanted Electronic Devices. Circ. Arrhythmia Electrophysiol. 2022;15:e010304. doi: 10.1161/CIRCEP.121.010304. - DOI - PubMed
    1. Glotzer T.V., Daoud E.G., Wyse D.G., Singer D.E., Ezekowitz M.D., Hilker C., Miller C., Qi D., Ziegler P.D. The Relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk the trends study. Circ. Arrhythmia Electrophysiol. 2009;2:474–480. doi: 10.1161/CIRCEP.109.849638. - DOI - PubMed

LinkOut - more resources